Note 12 - Noncontrolling Interests (Details Textual) $ / shares in Units, $ in Thousands		12 Months Ended
Nov. 12, 2020 USD ($) $ / shares	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
Temporary Equity, Accretion to Redemption Value		$ 0	$ 457
SEED Therapeutics Inc. [Member]
Share Price (in dollars per share) \| $ / shares	$ 7.5375
Proceeds from Issuance Initial Public Offering	$ 50,000
Series A-2 Preferred Shares [Member] \| Research Collaboration and License Agreement with Eli Lilly [Member] \| SEED Therapeutics Inc. [Member]
Annual Return, Percentage	8.00%
Number of Annual Redemption Installments	3

Represents the annual return percentage under the collaboration agreement.

No definition available.

Name:	bysi_AnnualReturnPercentage
Namespace Prefix:	bysi_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of annual redemption installments.

+ References

No definition available.

+ Details

Name:	bysi_NumberOfAnnualRedemptionInstallments
Namespace Prefix:	bysi_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash inflow associated with the amount received from entity's first offering of stock to the public.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details

Name:	us-gaap_ProceedsFromIssuanceInitialPublicOffering
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name:	us-gaap_SharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Value of accretion of temporary equity to its redemption value during the period.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1

+ Details

Name:	us-gaap_TemporaryEquityAccretionToRedemptionValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	dei_LegalEntityAxis=bysi_SEEDTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=bysi_SeriesA2PreferredSharesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: